Serva

MIT Validates Serva Energy's Novel Production Method of Life-saving Actinium-225 Isotope

Retrieved on: 
수요일, 11월 1, 2023
Actinium, MIT, Nuclear medicine, Radiology, Thought, Clinical professor, Radiopharmaceutical, Isotopes of radium, MIT Nuclear Research Reactor, Targeted alpha-particle therapy, Mayo Clinic, Uranium mining, Radiochemistry, Serva

TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.

Key Points: 
  • TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.
  • It's the latest milestone in Serva's development of commercial quantities of Ac-225 needed for next-generation Targeted Alpha Therapies.
  • In June, Serva Energy announced a novel reactor-based method to produce significantly greater amounts of medical-grade Ac-225—marking the first time a commercial entity has used a conventional nuclear reactor to create the ultra-rare isotope.
  • "Plans to quickly optimize and scale up any production of this potentially critical medical isotope will be crucial in establishing a reliable supply of Ac-225."